Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose prednisone added to Fabry disease background therapy in adults with cardiac involvement
2025-521408-24-00Phase 3Authorised
- Sponsor
- Medical University of Lodz
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prednisone in Fabry disease (FD) (2 arms), sponsored by Medical University of Lodz. Primary endpoint: Reduction in high-sensitivity troponin T. Planned start Mar 2026; status: authorised.
02
Drugs
prednisone
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2025-521408-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521408-24-00.